Aristada — Competitive Intelligence Brief

Aristada (ARIPIPRAZOLE LAUROXIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed D(2) dopamine receptor Neuroscience Small molecule

Target snapshot

Aristada (ARIPIPRAZOLE LAUROXIL) — Alkermes Inc. Aristada works by blocking dopamine receptors in the brain to help regulate abnormal thought and behavior patterns.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aristada TARGET	ARIPIPRAZOLE LAUROXIL	Alkermes Inc	marketed		D(2) dopamine receptor	2015-01-01
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Aripiprazole Augmentation	Aripiprazole Augmentation	Centre for Addiction and Mental Health	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Adjunctive asenapine	Adjunctive asenapine	Lori Davis, MD	marketed	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
Placebo Asenapine	Placebo Asenapine	Organon and Co	phase 3	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.